Insider Selling: Galectin Therapeutics Inc. (NASDAQ:GALT) Insider Sells 13,654 Shares of Stock

Galectin Therapeutics Inc. (NASDAQ:GALT) insider Khurram Jamil sold 13,654 shares of Galectin Therapeutics stock in a transaction dated Monday, December 23rd. The stock was sold at an average price of $0.88, for a total value of $12,015.52. Following the completion of the sale, the insider now owns 26,346 shares of the company’s stock, valued at approximately $23,184.48. The trade was a 34.14 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Galectin Therapeutics Stock Up 32.2 %

Shares of Galectin Therapeutics stock opened at $1.15 on Friday. The business has a fifty day simple moving average of $2.34 and a 200 day simple moving average of $2.43. The stock has a market cap of $72.18 million, a PE ratio of -1.58 and a beta of 0.69. Galectin Therapeutics Inc. has a 12 month low of $0.73 and a 12 month high of $4.27.

Hedge Funds Weigh In On Galectin Therapeutics

Institutional investors have recently modified their holdings of the stock. Marshall Wace LLP bought a new position in Galectin Therapeutics during the 2nd quarter worth approximately $43,000. Rhumbline Advisers acquired a new stake in Galectin Therapeutics in the second quarter worth $44,000. Gladstone Institutional Advisory LLC acquired a new stake in Galectin Therapeutics in the third quarter worth $60,000. Barclays PLC boosted its position in shares of Galectin Therapeutics by 309.0% during the third quarter. Barclays PLC now owns 28,587 shares of the company’s stock worth $79,000 after purchasing an additional 21,598 shares in the last quarter. Finally, JPMorgan Chase & Co. grew its holdings in shares of Galectin Therapeutics by 161.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 30,628 shares of the company’s stock valued at $84,000 after buying an additional 18,907 shares during the period. 11.68% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have recently issued reports on GALT shares. HC Wainwright reaffirmed a “neutral” rating on shares of Galectin Therapeutics in a research note on Friday. StockNews.com raised shares of Galectin Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, November 20th.

Galectin Therapeutics Company Profile

Galectin Therapeutics Inc, a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma.